The iCrucumab Biosimilar Anti-FLT1 Antibody is a cutting-edge tool for researchers studying the FLT1 protein, a receptor essential in angiogenesis and vascular development. This antibody, derived from innovative biosimilar technology, is highly specific and sensitive in detecting FLT1 in various samples, making it ideal for use in studies related to cancer, cardiovascular diseases, and other angiogenesis-related conditions.FLT1, also known as the vascular endothelial growth factor receptor 1 (VEGFR1), is a key player in the regulation of blood vessel formation and has been implicated in tumor growth and metastasis. By targeting FLT1 with the iCrucumab Biosimilar Anti-FLT1 Antibody, researchers can gain insights into the role of this receptor in disease progression and potentially identify new therapeutic strategies for combating diseases like cancer.
This antibody is rigorously tested and validated for use in various applications, including Western blotting, immunohistochemistry, and flow cytometry, ensuring accurate and reliable results in experimental settings. With its unparalleled specificity and versatility, the iCrucumab Biosimilar Anti-FLT1 Antibody is a valuable asset for researchers seeking to unravel the complexities of angiogenesis and develop targeted therapies for FLT1-associated diseases.
Product Name:
Icrucumab (Anti-FLT1) Biosimilar Antibody
Size:
100 ug
Product SKU:
HDBS0116
Target:
FLT1
Host Species:
Homo sapiens
Reactivity:
Human
Recommended Dilution:
ELISA 1:5000-10000; Flow Cyt 1:100
Antibody Type:
Monoclonal
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Storage & Shipping:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Common Name:
18F1, IMC-18F1, LY3012212
Description:
Anti-FLT1(icrucumab biosimilar) mAb
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Format:
Powder
Applications
ELISA, Flow Cyt
Antibody Isotype:
IgG1
Guarantee:
12 months from date of dispatch
Background:
Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
